Philip Tedbury

List of Publications by Year in Descending Order

123 papers	4,562 citations	36 h-index	63 g-index
133 ext. papers	5,342 ext. citations	7.8 avg, IF	5.49 L-index

#	Paper	IF	Citations
123	Structure-based virtual screening workflow to identify antivirals targeting HIV-1 capsid.. *Journal of Computer-Aided Molecular Design*, **2022**, 36, 193	4.2	1
122	Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations. *Viruses*, **2022**, 14, 1202	6.2	0
121	Design, Synthesis and Characterization of HIV-1 CA-Targeting Small Molecules: Conformational Restriction of PF74. *Viruses*, **2021**, 13,	6.2	5
120	Discovery of New Small Molecule Hits as Hepatitis B Virus Capsid Assembly Modulators: Structure and Pharmacophore-Based Approaches. *Viruses*, **2021**, 13,	6.2	4
119	Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase. *Microorganisms*, **2021**, 9,	4.9	27
118	Molecular Dynamics Free Energy Simulations Reveal the Mechanism for the Antiviral Resistance of the M66I HIV-1 Capsid Mutation. *Viruses*, **2021**, 13,	6.2	5
117	The SMC5/6 complex compacts and silences unintegrated HIV-1 DNA and is antagonized by Vpr. *Cell Host and Microbe*, **2021**, 29, 792-805.e6	23.4	12
116	Novel PF74-like small molecules targeting the HIV-1 capsid protein: Balance of potency and metabolic stability. *Acta Pharmaceutica Sinica B*, **2021**, 11, 810-822	15.5	7
115	Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. *Current Research in Pharmacology and Drug Discovery*, **2021**, 2, 100045	3	4
114	Development of Human Immunodeficiency Virus Type 1 Resistance to 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0116721	5.9	2
113	Avoiding Drug Resistance in HIV Reverse Transcriptase. *Chemical Reviews*, **2021**, 121, 3271-3296	68.1	18
112	Potency and metabolic stability: a molecular hybrid case in the design of novel PF74-like small molecules targeting HIV-1 capsid protein.. *RSC Medicinal Chemistry*, **2021**, 12, 2031-2044	3.5	0
111	Rotten to the core: antivirals targeting the HIV-1 capsid core.. *Retrovirology*, **2021**, 18, 41	3.6	5
110	Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs. *Pathogens*, **2020**, 9,	4.5	22
109	Effect of P-body component Mov10 on HCV virus production and infectivity. *FASEB Journal*, **2020**, 34, 9433-9449	0.9	4
108	7-Deaza-7-fluoro modification confers on 4′-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety. *Antiviral Research*, **2020**, 176, 104744	10.8	6
107	Toward Structurally Novel and Metabolically Stable HIV-1 Capsid-Targeting Small Molecules. *Viruses*, **2020**, 12,	6.2	12

106	Chemical profiling of HIV-1 capsid-targeting antiviral PF74. *European Journal of Medicinal Chemistry*, **2020**, 200, 112427	6.8	12
105	Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H. *Accounts of Chemical Research*, **2020**, 53, 218-230	24.3	17
104	HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains. *Nature Communications*, **2020**, 11, 3505	17.4	48
103	Novel HIV-1 capsid-targeting small molecules of the PF74 binding site. *European Journal of Medicinal Chemistry*, **2020**, 204, 112626	6.8	10
102	Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail. *Journal of Virology*, **2020**, 94,	6.6	2
101	Conformational Changes in HIV-1 Reverse Transcriptase that Facilitate Its Maturation. *Structure*, **2019**, 27, 1581-1593.e3	5.2	3
100	Glycosylated diphyllin as a broad-spectrum antiviral agent against Zika virus. *EBioMedicine*, **2019**, 47, 269-283	8.8	18
99	Determinants of Active-Site Inhibitor Interaction with HIV-1 RNase H. *ACS Infectious Diseases*, **2019**, 5, 1963-1974	5.5	6
98	CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	11
97	Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase. *Pharmaceuticals*, **2019**, 12,	5.2	25
96	Novel Intersubunit Interaction Critical for HIV-1 Core Assembly Defines a Potentially Targetable Inhibitor Binding Pocket. *MBio*, **2019**, 10,	7.8	11
95	Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker. *European Journal of Medicinal Chemistry*, **2019**, 166, 390-399	6.8	11
94	Strain-specific effect on biphasic DNA binding by HIV-1 integrase. *Aids*, **2019**, 33, 588-592	3.5	6
93	Analysis of HIV-1 Matrix-Envelope Cytoplasmic Tail Interactions. *Journal of Virology*, **2019**, 93,	6.6	15
92	Effects of Moloney Leukemia Virus 10 Protein on Hepatitis B Virus Infection and Viral Replication. *Viruses*, **2019**, 11,	6.2	5
91	HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation. *Journal of Virology*, **2019**, 94,	6.6	12
90	Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus. *Viruses*, **2019**, 11,	6.2	5
89	Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores. *ACS Infectious Diseases*, **2019**, 5, 750-758	5.5	8

88	5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. *European Journal of Medicinal Chemistry*, **2019**, 164, 179-192	6.8	11
87	Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2. *Journal of Medicinal Chemistry*, **2019**, 62, 1125-1137	8.3	32
86	The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells. *MSphere*, **2018**, 3,	5	12
85	4Ⅴ-Ethynyl-2-fluoro-2Ⅴ-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. *Current Opinion in HIV and AIDS*, **2018**, 13, 294-299	4.2	53
84	Antiretroviral potency of 4Ⅴ-ethynyl-2Ⅴ-fluoro-2Ⅴ-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2721-2728	5.1	10
83	Contribution of a Multifunctional Polymerase Region of Foot-and-Mouth Disease Virus to Lethal Mutagenesis. *Journal of Virology*, **2018**, 92,	6.6	3
82	6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H. *European Journal of Medicinal Chemistry*, **2018**, 156, 680-691	6.8	18
81	6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity. *European Journal of Medicinal Chemistry*, **2018**, 156, 652-665	6.8	14
80	Effect of tRNA on the Maturation of HIV-1 Reverse Transcriptase. *Journal of Molecular Biology*, **2018**, 430, 1891-1900	6.5	5
79	Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes. *Frontiers in Microbiology*, **2018**, 9, 1754	5.7	11
78	Visualization of HIV-1 RNA Transcription from Integrated HIV-1 DNA in Reactivated Latently Infected Cells. *Viruses*, **2018**, 10,	6.2	6
77	Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation. *MBio*, **2018**, 9,	7.8	8
76	The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase. *Cell Chemical Biology*, **2018**, 25, 1268-1278.e3	8.2	16
75	Capsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking to Sites of Viral DNA Integration. *Cell Host and Microbe*, **2018**, 24, 392-404.e8	23.4	96
74	Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa. *Journal of Medical Virology*, **2017**, 89, 106-111	19.7	10
73	Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. *Scientific Reports* , **2017**, 7, 43908	4.9	25
72	6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase. *European Journal of Medicinal Chemistry*, **2017**, 128, 168-179	6.8	14
71	Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity. *Journal of Medicinal Chemistry*, **2017**, 60, 5045-5056	8.3	27

70	Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	15
69	Molecular and Functional Bases of Selection against a Mutation Bias in an RNA Virus. *Genome Biology and Evolution*, **2017**, 9, 1212-1228	3.9	10
68	Exposing HIV's weaknesses. *Journal of Biological Chemistry*, **2017**, 292, 6027-6028	5.4	2
67	Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase. *European Journal of Medicinal Chemistry*, **2017**, 133, 85-96	6.8	15
66	3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	12
65	Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H. *European Journal of Medicinal Chemistry*, **2017**, 141, 149-161	6.8	28
64	A 2-Hydroxyisoquinoline-1,3-Dione Active-Site RNase H Inhibitor Binds in Multiple Modes to HIV-1 Reverse Transcriptase. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	11
63	Multiplex single-cell visualization of nucleic acids and protein during HIV infection. *Nature Communications*, **2017**, 8, 1882	17.4	37
62	Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA). *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 9274-9	11.5	53
61	3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H. *Journal of Medicinal Chemistry*, **2016**, 59, 6136-48	8.3	31
60	Structural and Molecular Determinants of Membrane Binding by the HIV-1 Matrix Protein. *Journal of Molecular Biology*, **2016**, 428, 1637-55	6.5	55
59	3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations. *Journal of Medicinal Chemistry*, **2016**, 59, 2648-59	8.3	31
58	Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 367-71	5.1	6
57	The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple Functionalities. *Nano Letters*, **2016**, 16, 1746-53	11.5	31
56	Biochemical evidence of a role for matrix trimerization in HIV-1 envelope glycoprotein incorporation. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E182-90	11.5	41
55	Trimer Enhancement Mutation Effects on HIV-1 Matrix Protein Binding Activities. *Journal of Virology*, **2016**, 90, 5657-5664	6.6	16
54	Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H. *Journal of Medicinal Chemistry*, **2016**, 59, 5051-62	8.3	42
53	HIV-1 gag: an emerging target for antiretroviral therapy. *Current Topics in Microbiology and Immunology*, **2015**, 389, 171-201	3.3	18

52	Multifunctionality of a picornavirus polymerase domain: nuclear localization signal and nucleotide recognition. *Journal of Virology*, **2015**, 89, 6848-59	6.6	17
51	Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 3482-92	5.9	19
50	Oral administration of the nucleoside EFdA (4Ⱥethynyl-2-fluoro-2Ⱥdeoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 4190-8	5.9	61
49	The cytoplasmic tail of retroviral envelope glycoproteins. *Progress in Molecular Biology and Translational Science*, **2015**, 129, 253-84	4	16
48	4Ⱥmodified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus. *Hepatology*, **2015**, 62, 1024-36	11.2	36
47	STRUCTURAL VIROLOGY. X-ray crystal structures of native HIV-1 capsid protein reveal conformational variability. *Science*, **2015**, 349, 99-103	33.3	156
46	Elucidating the mechanism by which compensatory mutations rescue an HIV-1 matrix mutant defective for gag membrane targeting and envelope glycoprotein incorporation. *Journal of Molecular Biology*, **2015**, 427, 1413-1427	6.5	17
45	Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247. *FASEB Journal*, **2015**, 29, 70-80	0.9	1
44	Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor. *International Journal of Pharmaceutics*, **2014**, 461, 203-13	6.5	28
43	Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4Ⱥethynyl-2-fluoro-2Ⱥdeoxyadenosine (EFdA) using pre-steady-state kinetics. *Antiviral Research*, **2014**, 106, 1-4	10.8	14
42	SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4915-9	5.9	21
41	Antiviral drugs specific for coronaviruses in preclinical development. *Current Opinion in Virology*, **2014**, 8, 45-53	7.5	64
40	4ⱥEthynyl-2-fluoro-2Ⱥdeoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. *Journal of Biological Chemistry*, **2014**, 289, 24533-48	5.4	58
39	In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers. *European Journal of Pharmacology*, **2014**, 732, 86-95	5.3	13
38	Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4894-8	5.9	80
37	The role of matrix in HIV-1 envelope glycoprotein incorporation. *Trends in Microbiology*, **2014**, 22, 372-8	12.4	42
36	Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors. *Viruses*, **2014**, 6, 3535-62	6.2	22
35	Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. *Retrovirology*, **2013**, 10, 65	3.6	30

34	Effects of substitutions at the 4V and 2 positions on the bioactivity of 4V-ethynyl-2-fluoro-2V-deoxyadenosine. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 6254-64	5.9	28
33	Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure. *PLoS Pathogens*, **2013**, 9, e1003739	7.6	54
32	The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. *PLoS Pathogens*, **2013**, 9, e1003125	7.6	85
31	Evaluation of Combinations of 4V-Ethynyl-2-Fluoro-2V-Deoxyadenosine with Clinically Used Antiretroviral Drugs. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4554-4558	5.9	16
30	Virus Assembly **2013**, 1-11		
29	Antiviral therapies: focus on hepatitis B reverse transcriptase. *International Journal of Biochemistry and Cell Biology*, **2012**, 44, 1060-71	5.6	34
28	Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 2048-61	5.9	27
27	Hepatitis C virus-induced autophagy is independent of the unfolded protein response. *Journal of Virology*, **2012**, 86, 10724-32	6.6	48
26	Mechanism of interaction of human mitochondrial DNA polymerase with the novel nucleoside reverse transcriptase inhibitor 4V-ethynyl-2-fluoro-2V-deoxyadenosine indicates a low potential for host toxicity. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 1630-4	5.9	21
25	Biochemical mechanism of HIV-1 resistance to rilpivirine. *Journal of Biological Chemistry*, **2012**, 287, 38110-23	5.4	51
24	Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4718-28	5.9	72
23	Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. *Nucleic Acids Research*, **2012**, 40, 345-59	20.1	13
22	Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4V-ethynyl-2-fluoro-2V-deoxyadenosine in vitro and in vivo. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4707-12	5.9	44
21	The subcellular localization of the hepatitis C virus non-structural protein NS2 is regulated by an ion channel-independent function of the p7 protein. *Journal of General Virology*, **2011**, 92, 819-30	4.9	37
20	Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 11549-54	11.5	109
19	The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine. *Journal of Biological Chemistry*, **2010**, 285, 38700-9	5.4	39
18	A comparative analysis of the fluorescence properties of the wild-type and active site mutants of the hepatitis C virus autoprotease NS2-3. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2010**, 1804, 212-22	4	6
17	Mechanism of inhibition of HIV-1 reverse transcriptase by 4V-Ethynyl-2-fluoro-2V-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. *Journal of Biological Chemistry*, **2009**, 284, 35681-91	5.4	104

16	Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. *Journal of Molecular Biology*, **2009**, 385, 693-713	6.5	355
15	Hepatitis C Virus **2009**, 47-69		
14	2¥deoxy-4¥C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. *International Journal of Biochemistry and Cell Biology*, **2008**, 40, 2410-20	5.6	90
13	Biochemistry. RT slides home. *Science*, **2008**, 322, 1059-60	33.3	1
12	Characterisation of the role of zinc in the hepatitis C virus NS2/3 auto-cleavage and NS3 protease activities. *Journal of Molecular Biology*, **2007**, 366, 1652-60	6.5	21
11	Structures of Wild-Type and AZT-Resistant HIV-1 Reverse Transcriptase Complexed with AZTppppA Yield Insights into the Nucleotide Excision Mechanism. *FASEB Journal*, **2007**, 21, A640	0.9	
10	LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. *Biochemical Journal*, **2006**, 393, 107-15	3.8	67
9	Biochemistry and cell biology of mammalian scavenger receptors. *Atherosclerosis*, **2005**, 182, 1-15	3.1	273
8	Identification using phage display of peptides promoting targeting and internalization into HPV-transformed cell lines. *Journal of Molecular Recognition*, **2005**, 18, 175-82	2.6	21
7	Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs. *International Journal of Biochemistry and Cell Biology*, **2004**, 36, 1706-15	5.6	39
6	Trapping HIV-1 reverse transcriptase before and after translocation on DNA. *Journal of Biological Chemistry*, **2003**, 278, 16280-8	5.4	66
5	Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. *Journal of Virology*, **2003**, 77, 8548-54	6.6	47
4	Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. *EMBO Journal*, **2002**, 21, 6614-24	13	167
3	The M184V mutation reduces the selective excision of zidovudine 5¥monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. *Journal of Virology*, **2002**, 76, 3248-56	6.6	81
2	Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. *EMBO Journal*, **2001**, 20, 1449-61	13	360
1	Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. *Journal of Molecular Biology*, **1998**, 284, 1095-111	6.5	302